Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
—
—
—
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
Customise key metrics, see detailed forecasts, download stock data and more
A significant proportion of promoter holdings is pledged
In last 3 months, mutual fund holding of the company has almost stayed constant
The Exchange had sought clarification from Nectar Lifesciences Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. | Download
The Exchange had sought clarification from Nectar Lifesciences Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. | Download
Final • Div/Share: ₹ 0.05
Increased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 11.45%